Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B.
Two of the most controversial topics in antifungal therapy are the value of short-course therapy with amphotericin B and the use of amphotericin B in combination with other therapeutic agents. In each case, experimental data provide support for clinical use, but adequate clinical studies are sparse. Until more clinical studies are done, use of these regimens should be restricted to specific groups of patients.
Medoff
G
G
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000666:Amphotericin B; D005437:Flucytosine; D013752:Tetracycline; D012293:Rifampin